PCOS name – A global consortium plans to replace PCOS with PMOS, citing metabolic and endocrine features and broader impact. Here’s what it changes.

A long-familiar medical label is about to be retired—and for many patients, that shift could affect how their symptoms are recognized, studied, and treated.

A global science consortium has announced that polycystic ovary syndrome (PCOS) will no longer be used as the official term.. The condition still exists. but the group says the name has been misleading because it does not fully reflect the disorder’s metabolic and endocrine features. including evidence that it likely affects people beyond those assigned female at birth.

In the new policy paper, the panel proposes replacing PCOS with polyendocrine metabolic ovarian syndrome (PMOS).. The consortium’s stated goals are practical as well as social: to improve diagnostic accuracy. reduce stigma. and strengthen research efforts that may have been constrained by the way the condition has been framed for decades.

The change matters because PCOS has been estimated to affect more than 170 million people.. For many, the consequences have been broader than reproductive health alone.. The report highlights “multisystem health impacts. ” describing links that can include obesity and hypertension. as well as depression and eating disorders.. It also points to symptoms such as acne and infertility. emphasizing that the syndrome’s footprint extends across multiple body systems.

One of the core reasons for reclassification is that the old name helped reinforce an assumption that the disorder is mainly gynecological and ovarian-focused.. The authors argue that evidence increasingly contradicts that narrow view. showing that the condition’s endocrine and metabolic characteristics are central rather than secondary.

The consortium also ties the proposed rename to the realities of care.. The paper states that many people go undiagnosed or misdiagnosed. and that many others report dissatisfaction with their medical treatment and experience severe stigma.. In their view. changing the terminology is intended to address not only scientific categorization but also the day-to-day consequences for patients trying to get help.

Efforts to revise the label have been repeatedly proposed and delayed over the past two decades, the authors note.. Now. the consortium says it has moved from intermittent discussion toward a coordinated pathway for adoption. aiming to turn the concept of a new name into an internationally recognized standard.

A key next step involves policy implementation.. The paper. published in The Lancet. lays out a plan for the World Health Organization and the International Classification of Diseases to adopt PMOS over the next three years.. If the schedule holds, the new terminology could become the international standard in 2028.

Even before the policy timeline completes, researchers see scientific opportunities in the redesignation. The consortium hopes that PMOS will encourage new studies into the syndrome—particularly genetic components—and help clarify how the condition develops and progresses.

At the same time, the report underscores a major clinical gap: there is currently no U.S.. Food and Drug Administration–approved therapeutic specifically for the condition.. For patients. that absence means that improved recognition. clearer classification. and stronger research priorities could be especially important in the effort to translate science into treatment options.

For clinicians and researchers, terminology can shape what gets measured and how findings are interpreted.. By placing endocrine and metabolic features front and center—rather than anchoring the label primarily to ovarian appearance—the proposed name may help align research questions with the full range of symptoms reported in the paper.

For patients, the rename is also about lived experience. When a condition’s name suggests a narrower scope, it can affect how quickly people are believed, how symptoms are connected, and whether comorbid problems such as mental health issues and metabolic complications are actively screened.

The decision also raises a broader question in medicine: how medical language evolves as evidence changes.. The consortium’s argument is that PCOS was never a complete description of what the syndrome entails. and that a more accurate label could reduce stigma while improving the odds that future studies—and future therapies—are built around the condition as it truly presents across different people.

PCOS rename PMOS diagnosis endocrine health metabolic syndrome women’s health WHO classification